ALS neuron damage reversed with new compound

New compound targets neurons that initiate voluntary movement After 60 days of treatment, diseased brain cells look like healthy cells More research needed before clinical trial can be initiated CHICAGO and EVANSTON— Northwestern University scientists have identified the first compound that eliminates the ongoing degeneration of upper motor neurons that become diseased and are a…

Details

Pregnancy, stress, sleep issues, physiology among women’s unique cardiovascular concerns

DALLAS, Feb. 23, 2021 — Women face many female-specific risks for heart disease and stroke, including pregnancy, physical and emotional stress, sleep patterns and many physiological factors, according to multiple studies highlighted in this year’s Go Red for Women® special issue of the Journal of the American Heart Association, published online today. “Although cardiovascular disease…

Details

JDRF announces new Center of Excellence in New England to advance type 1 diabetes research

NEW YORK, NY, February 23, 2021–JDRF, the leading global organization funding type 1 diabetes (T1D) research, announces, in collaboration with the Harvard Stem Cell Institute, the launch of the JDRF Center of Excellence in New England. Led by Harvard Stem Cell Institute co-director Douglas Melton, Ph.D. and JDRF scientific staff leader Esther Latres, Ph.D., Assistant…

Details

SLAS and The Pistoia Alliance partner to promote life sciences startup companies

Oak Brook, IL – The Society for Laboratory Automation and Screening (SLAS) is pleased to announce a collaboration with the Pistoia Alliance to support and promote innovative life sciences start-ups and emerging companies. The SLAS Ignite Program is a multi-pronged initiative to promote innovation, pioneering research, start-up and emerging companies and their products, and…

Details

ESMO Targeted Anticancer Therapies Congress 2021

Lugano, Switzerland, 23 February 2021 – The ESMO Targeted Anticancer Therapies Congress 2021, designed for basic scientists, physicians and translational researchers belonging to academic settings, industry and regulatory agencies will be held as a virtual meeting. (1) The scientific programme will provide new data and insightful presentations in the area of drug discovery and development…

Details

Vaccines Adapted for Variants Will Not Need Lengthy Testing, F.D.A. Says

The Food and Drug Administration said on Monday that vaccine developers would not need to conduct lengthy randomized controlled trials for vaccines that have been adapted to protect against concerning coronavirus variants. The recommendations, which call for small trials more like those required for annual flu vaccines, would greatly accelerate the review process at a…

Details